What are the main functions and effects of Dacomitinib? What diseases does it have significant efficacy in treating?

Dacomitinib (Dacomitinib) is an oral, irreversible tyrosine kinase inhibitor (TKI), mainly targeting epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). As a second-generation EGFR-TKI, dacomitinib can irreversibly inhibit EGFR family members (EGFR/HER1, pan>HER2 and HER4) activities, thereby blocking the proliferation signaling pathway of cancer cells, and has a strong anti-tumor effect on lung cancer patients with EGFR mutations.

The main indication for dacomitinib is the treatment of patients with EGFRexon19 deletion (Exon 19del) or exon 21 Patients with advanced or metastatic non-small cell lung cancer (NSCLC) with L858Rmutations. Clinical studies have shown that compared with first-generation EGFR-TKIs (such as gefitinib and erlotinib), dacomitinib has better performance in terms of progression-free survival (PFS) and overall survival (OS), and can delay disease progression and improve patient survival time.

In addition, due to its irreversible binding to EGFR, dacomitinib has certain advantages over the first-generation EGFR-TKI in terms of drug resistance control. However, the side effects of this drug are also obvious. Common adverse reactions include rash, diarrhea, stomatitis, etc. Therefore, it is necessary to pay close attention to the patient's tolerance during use, and adjust the dosage or take corresponding supportive treatment according to individual conditions.

In general, dacomitinib, as a second-generation EGFR-TKI, plays an important role in the treatment of EGFR mutation-positive advanced non-small cell lung cancer, and is especially suitable for first-line treatment. For patients, when choosing dacomitinib, they need to weigh the efficacy and side effects under the guidance of a doctor, and make reasonable treatment decisions based on their personal condition.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro